Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Non–Small-Cell Lung Cancer

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis

“…Two SBRT studies reporting the results of the same phase 2 trial complemented each other, and were counted as 1 study. One phase 3 study comparing SBRT and surgery (only the SBRT data was used) [12], 10 phase 2 [20-31], 1 phase 1 [32], and 56 retrospective [33-51,53-89] photon SBRT studies were included in the survival outcome comparison analysis. Among them, treatment-related toxicities were reported in all the prospective studies [12,20-32], and 40 retrospective studies [34,37,39-40,42,44-47,49,52-61,65,67-73,76-78, 80-82,84-89].…”

“…For 1 retrospective study without toxicity reporting, a similar retrospective study reporting on patients from the same institution treated in the same fashion and in similar time periods was used in the toxicity analysis [51,52]. Patterns of failure were analyzed based on the information provided in 57 studies, which included 1 phase 3 (only the SBRT data was used), 10 phase 2, 0 phase 1, and 46 retrospective studies [12,20-31,34-46,48-51,54-57,59-65,68-71,73-75,77-79,82,84-90]. Among them, 1 retrospective study was not included in the survival outcome or toxicity profile analysis [90].…”

Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

“…The impact of the pretreatment maximum standard uptake value (SUVmax) on FDG-PET has been reported by some studies (23)(24)(25)(26), although it is controversial. Shultz et al (27) identified imaging-based biomarkers (tumor size, contact with the mediastinal pleura, and SUVmax) and found them to be associated with distant progression. In the current study, it was found that mGPS had a correlation with increased DM.…”

FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer

“…While our findings are consistent with the conclusions of a recent meta-analysis that included patients undergoing any form of lung radiotherapy,[30] a definitive association between pre-treatment SUV max and LR specifically in patients undergoing SBRT, a radiotherapy technique with a low rate of LR, has not yet been demonstrated. Several prior studies limited to SBRT patients have not found an association between SUV max and LR [24-26, 28, 31]. Other small retrospective studies have provided some evidence for an association between SUV max and LR, yet interpretability has been limited by a low number of LR events.…”

“…As with LR, no consensus exists regarding the association between pre-SBRT SUV max and DM. Multiple prior reports have failed to link SUV max to a higher risk of DM in the setting of SBRT for early-stage NSCLC [22, 26, 28, 31, 34]. Other studies have reported such an association, but differences in study design have limited their interpretation.…”